Osteosarcoma Metastatic, Osteosarcoma Recurrent
Conditions
Brief summary
A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment
Interventions
OTHERobservation
not applicable, observational study
Sponsors
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age at diagnosis of high grade osteosarcoma \>= 4 * Received first line treatment with HD IFO * Following HD IFO treatment, they have been diagnosed refractory disease and they satisfy at least one of the following criteria : 1. Relapsed in the first 24 month following the initial diagnosis, regardless of location and resectability 2. Lung relapsed disease with more than 2 nodules diagnosed over 24 months from the initial diagnosis 3. Non resectable relapsed disease diagnosed over 24 months from the initial diagnosis Before or during GEMDOX treatment, eligible patients may have been subject to metastasectomy
Exclusion criteria
none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to Gemcitabina - Docetaxel Treatment | 12 months | assessed as overall survival (12 months) |
Countries
Italy
Outcome results
None listed